NCT00261547View on ClinicalTrials.gov

Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Chronic RejectionKidney Insufficiency

Interventions

DRUG

Rituximab

All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER